Key clinical point: A blood test that uses multiomics and machine learning detected colorectal cancer with high sensitivity and specificity.
Major finding: The test detected stage I and II colorectal cancer with 94% sensitivity and specificity.
Study details: A prospective study of 32 patients with colorectal cancer and 539 colonoscopy-confirmed negative control subjects.
Disclosures: The trial was sponsored by Freenome. Dr. Putcha is an employee of Freenome and has a relationship with Palmetto GBA.
Putcha G et al. 2020 GI Cancers Symposium, Abstract 66.